1-[bis(4-chlorophenyl)methyl]-3-{[3-(N-tertbutyloxy-carbonyl-N-methylamino)phenyl](methylsulfonyl)-methylene}azetidine | 261922-90-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-[bis(4-chlorophenyl)methyl]-3-{[3-(N-tertbutyloxy-carbonyl-N-methylamino)phenyl](methylsulfonyl)-methylene}azetidine
• 英文别名: 1-[bis(4-chlorophenyl)methyl]-3-{[3-(N-tertbutyloxycarbonyl-N-methylamino)phenyl] (methylsulfonyl)-methylene}azetidine；tert-butyl N-[3-[[1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene]-methylsulfonylmethyl]phenyl]-N-methylcarbamate
• CAS: 261922-90-1
• 化学式: C₃₀H₃₂Cl₂N₂O₄S
• 分子量: 587.567
• InChiKey: WWOWASLCKRSULU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  39
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  75.3
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-[bis(4-chlorophenyl)methyl]-3-{[3-(N-tertbutyloxy-carbonyl-N-methylamino)phenyl](methylsulfonyl)-methylene}azetidine 、 在 乙酸乙酯 、 magnesium sulfate 、 甲烷 、 crystals 作用下， 以 1,4-二氧六环 为溶剂， 反应 20.0h， 以1.3 g of 1-[bis(4-chlorophenyl)methyl]-3-[(3-methylaminophenyl)(methylsulfonyl)methylene]azetidine are obtained in the form of white crystals melting at 228° C. [NMR spectrum in DMSO-d6, T=300K, δ in ppm (300 MHz): 2.65 (3H, s, J=6 Hz, NCH3), 2.95 (3H, s, SCH3), 3.80 (2H, s, NCH2), 4.20 (2H, s, NCH2), 4.80 (1H, s, NCH), 5.85 (1H, q, J=6 Hz, NH), 6.55 (3H, m, 3 CH arom.), 7.15 (1H, t, J=7 Hz, CH arom.), 7.40 (4H, d, J=7 Hz, 4CH arom.), 7.50 (4H, m, 4CH arom.)]的产率得到1-[bis(4-chlorophenyl)methyl]-3-[(3-methylaminophenyl)-(methylsulfonyl)methylene]azetidine
  参考文献：
  名称：

  Acetindine derivatives, their preparation and medicaments containing them

  摘要：

  本发明涉及公开了式的氮杂四元环衍生物：它们的光学异构体、盐、制备方法以及包含它们的药物。

  公开号：

  US06858603B2

文献信息

• Azetidine derivatives, their preparation and medicaments containing them
  申请人：——

  公开号：US20020035102A1

  公开（公告）日：2002-03-21

  The invention concerns compounds of formula (1) wherein: R represents a chain (A) or (B); R 1 is methyl or ethyl; R 2 is either an optionally substituted aromatic or an optionally substituted heteroaromatic ring; R 3 and R 4 , identical or different, are either an optionally substituted aromatic or an optionally substituted heteroaromatic ring; R′ represents a hydrogen atom or a —CO—alk radical, their optical isomers, their salts, their preparation and medicines containing them. 1

  本发明涉及通式(1)的化合物，其中：R代表链(A)或(B)；R1是甲基或乙基；R2是可任选取代的芳香环或可任选取代的杂芳香环；R3和R4，相同或不同，是可任选取代的芳香环或可任选取代的杂芳香环；R′代表氢原子或—CO—烷基，它们的光学异构体，它们的盐，它们的制备方法以及含有它们的药物。
• Pharmacological uses of azetidine derivatives
  申请人：Achard Daniel

  公开号：US20050130953A1

  公开（公告）日：2005-06-16

  A method of treating or preventing Alzheimer's disease, Parkinson's Disease and/or schizophrenia, this method comprising administering to a patient in need of such treatment a compound of formula: in which R, R 3 and R 4 are as defined in the specification.

  一种治疗或预防阿尔茨海默病、帕金森病和/或精神分裂症的方法，该方法包括向需要此类治疗的患者施用以下化合物：其中R、R3和R4如规范中所定义。
• Azetidine derivatives, their preparation and pharmaceutical compositions containing them
  申请人：——

  公开号：US20030055033A1

  公开（公告）日：2003-03-20

  Compounds of formula: 1 in which R represents a CR 1 R 2 , C═C(R 5 )SO 2 R 6 or C═C(R 7 )SO 2 alk radical, their preparation and the pharmaceutical compositions containing them.

  化合物的公式：其中R代表CR1R2、C═C(R5)SO2R6或C═C(R7)SO2alk基团，它们的制备以及含有它们的制药组合物。
• AZETIDINE DERIVATIVES, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM
  申请人：Achard Daniel

  公开号：US20060270649A1

  公开（公告）日：2006-11-30

  Disclosed are azetidine derivatives of formula: their optical isomers, their salts, their preparation and medicaments containing them.

  本发明涉及一种式子为的氮杂环丙烷衍生物，包括其光学异构体、其盐、其制备方法以及含有它们的药物。
• DERIVES D'AZETIDINE, LEUR PREPARATION ET LES MEDICAMENTS LES CONTENANT
  申请人：Aventis Pharma S.A.

  公开号：EP1112251B1

  公开（公告）日：2003-05-07